NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
Eli Lilly and Company
Cyteir Therapeutics, Inc.
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)